Home    Back

 23. Prion disease
 [ 3 clinical trials,    5 drugs(DrugBank: 2 drugs),    0 target gene / 0 target pathway

Searched query = "Prion disease", "Creutzfeldt Jakob disease", "Gerstmann Straussler Scheinker syndrome", "Fatal familial insomnia", "Kuru disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022233-28-IT20/06/201125 September 2012Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals - Doxycycline in FFI individualsSubjects born between 1958 and 1969 belonging to the Treviso FFI family, tested previously for Prion D178N/129M mutation
MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: BASSADO
Pharmaceutical Form: Tablet
INN or Proposed INN: DOXYCYCLINE HYCLATE
CAS Number: 24390-14-5
Concentration unit: 1X 100 milligrams/millilitre
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
IST. DI RICERCHE FARMACOLOG. M. NEGRIAuthorisedFemale: yes
Male: yes
Italy
2EUCTR2006-001858-27-IT21/06/200619 March 2012A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - NDA randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - NDCreutzfeldt-Jakob Disease.
MedDRA version: 9.1 Level: LLT Classification code 10011384 Term: Creutzfeldt-Jakob disease
Trade Name: BASSADO 10CPS 100MG
Pharmaceutical Form: Tablet
INN or Proposed INN: Doxycycline
CAS Number: 24390-14-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
ISTITUTO NEUROLOGICO CARLO BESTAAuthorisedFemale: yes
Male: yes
Italy
3NCT00183092April 200519 October 2017CJD (Creutzfeldt-Jakob Disease) Quinacrine StudyNovel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob DiseaseCreutzfeldt-Jakob DiseaseDrug: Quinacrine;Drug: PlaceboUniversity of California, San FranciscoNational Institute on Aging (NIA)Not recruiting18 YearsN/AAll69Phase 2United States